WHEN: Wednesday, March 22, 12:00pm-1:00pm
WHERE: TMEC 448 in Harvard Medical School
HOSTED BY: GSAS Science Policy Group
Our guest will be Bruce Zetter, PhD who is the Charles Nowiszewski Professor in the Departments of Cell Biology and Surgery at Harvard Medical School. His research is focused on the nature of highly aggressive, metastatic, late-stage cancers and he has servred as expert witness for the United States Senate Cancer Coalition hearings in Washington.
Please RSVP! Lunch will be provided - please let us know whether you can attend so we can make sure to bring enough food!
This is PART 3 of a seven-part series that will happen throughout Spring semester about the 21st Century Cures Act. The 21st Century Cures Act was passed by Congress late last year and promises to provide funding for many research topics such as precision medicine, brain disorders and the opioid epidemic. In addition, the new law changes important aspects of how drugs get approved through the FDA by increasing the reliance on surrogate endpoints and patient advocacy groups, for example. Some argue that this law offers great promise for combatting the big problems that still remain in the biomedical sciences, but others are worried that loosening regulations at the FDA could undermine the rigorous approval process the FDA is known for.
We will keep you updated as these events get closer! Please join us as often as you can for pizza and conversation about science policy with our expert faculty!
Contact Chamith Fonseka (chamith_fonseka@hms.harvard.edu) with any questions.